Starboard's Jeff Smith told Pfizer in a meeting last week that they need to improve their return on investments in R&D and ...

Jeff Smith, Starboard Value CEO, joins CNBC's 'Squawk on the Street' to discuss how he sees Pfizer going forward, potential ...

Adds Kenvue comment. Kenvue (NYSE:KVUE) needs to focus on fixing its skin, health and beauty segments, Jeff Smith, founder ...

Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...

Starboard Chief Executive Jeff Smith said that Kenvue, the Tylenol-maker spun out from Johnson & Johnson, should drill down on fixing its underperforming skin health and beauty segment, which he ...

Jeff Smith says pharma giant’s returns from recent efforts are ‘not adequate’ in speech at 13D activist investor conference ...

Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job.

Activist investor Starboard Value urged Pfizer’s (PFE) leadership to do “something different” and hold management accountable ...

Activist hedge fund Starboard Value believes the root cause of Pfizer’s issues are the low expected returns on its research and development investments, including investments done both internally and ...

Starboard Value contends that Kenvue, with strong consumer health brands like Tylenol and Listerine, is underperforming its ...

Starboard Value is raising the stakes in its $1 billion campaign for change at Pfizer (NYSE:PFE), urging the pharmaceutical ...